In vitro and in vivo anti-tumor activity of alectinib in tumor cells with NCOA4-RET

Rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) accounts for approximately 1–2% of all NSCLCs. To date, RET fusions that involve at least six fusion partners in NSCLC, such as KIF5B, CCDC6, NCOA4, TRIM33, CLIP1, and ERC1, have been identified. Recent clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Arai, Sachiko, Kita, Kenji, Tanimoto, Azusa, Takeuchi, Shinji, Fukuda, Koji, Sato, Hiroshi, Yano, Seiji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5650298/
https://www.ncbi.nlm.nih.gov/pubmed/29088743
http://dx.doi.org/10.18632/oncotarget.17900

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5650298/
https://www.ncbi.nlm.nih.gov/pubmed/29088743
http://dx.doi.org/10.18632/oncotarget.17900

Ejemplares similares